Humacyte (HUMA) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Humacyte (NASDAQ: HUMA) in the last few weeks:

• 4/28/2026 – Humacyte had its “buy” rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
• 4/28/2026 – Humacyte had its “buy” rating reaffirmed by BTIG Research. They now have a $3.00 price target on the stock.
• 4/21/2026 – Humacyte had its “buy” rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
• 4/11/2026 – Humacyte was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 4/10/2026 – Humacyte had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 3/27/2026 – Humacyte had its “buy” rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
• 3/27/2026 – Humacyte had its price target lowered by BTIG Research from $6.00 to $3.00. They now have a “buy” rating on the stock.
• 3/17/2026 – Humacyte had its “buy” rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.